scPharmaceuticals Stock Forecast, Price & News

scPharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions

Is scPharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" scPharmaceuticals stock.
View analyst ratings for scPharmaceuticals or view top-rated stocks.

How has scPharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

scPharmaceuticals' stock was trading at $7.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SCPH stock has decreased by 48.1% and is now trading at $4.03.
View which stocks have been most impacted by COVID-19.

When is scPharmaceuticals' next earnings date?

scPharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for scPharmaceuticals.

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals Inc. (NASDAQ:SCPH) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.07.
View scPharmaceuticals' earnings history.

What price target have analysts set for SCPH?

2 equities research analysts have issued twelve-month price objectives for scPharmaceuticals' shares. Their forecasts range from $5.00 to $15.00. On average, they expect scPharmaceuticals' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 148.1% from the stock's current price.
View analysts' price targets for scPharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are scPharmaceuticals' key executives?

scPharmaceuticals' management team includes the following people:

• John H. Tucker, President, Chief Executive Officer, CFO & Director (LinkedIn Profile)
• Mike Hassman, Senior Vice President-Technical Operations
• John Mohr, Senior VP-Clinical Development & Medical Affairs
• Rachael Nokes, Chief Accounting Officer & SVP-Finance
• Katherine Taudvin, Director-IR & Corporate Development

Who are some of scPharmaceuticals' key competitors?

Some companies that are related to scPharmaceuticals include Basilea Pharmaceutica (BPMUF), LumiraDx (LMDX), ORIC Pharmaceuticals (ORIC), OrganiGram (OGI), Ocular Therapeutix (OCUL), Adicet Bio (ACET), Dyne Therapeutics (DYN), Rigel Pharmaceuticals (RIGL), Pliant Therapeutics (PLRX), Vera Therapeutics (VERA), Affimed (AFMD), Veru (VERU), CytoDyn (CYDY), Rhythm Pharmaceuticals (RYTM) and Marinus Pharmaceuticals (MRNS).
View all of SCPH's competitors.

What other stocks do shareholders of scPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

When did scPharmaceuticals IPO?

(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is scPharmaceuticals' stock symbol?

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

Who are scPharmaceuticals' major shareholders?

scPharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Thomasville National Bank (0.05%). Company insiders that own scPharmaceuticals stock include Andrew J Schwab, Jack A Khattar, John H Tucker and Ra Capital Management, LP.
View institutional ownership trends for scPharmaceuticals.

Which institutional investors are buying scPharmaceuticals stock?

SCPH stock was purchased by a variety of institutional investors in the last quarter, including Thomasville National Bank. Company insiders that have bought scPharmaceuticals stock in the last two years include Andrew J Schwab, Jack A Khattar, John H Tucker, and Ra Capital Management, LP.
View insider buying and selling activity for scPharmaceuticals or or view top insider-buying stocks.

How do I buy shares of scPharmaceuticals?

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is scPharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $4.03.

How much money does scPharmaceuticals make?

scPharmaceuticals has a market capitalization of $110.24 million. The company earns $-32.21 million in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does scPharmaceuticals have?

scPharmaceuticals employs 27 workers across the globe.

What is scPharmaceuticals' official website?

The official website for scPharmaceuticals is www.scpharma.com.

Where are scPharmaceuticals' headquarters?

scPharmaceuticals is headquartered at 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830.

How can I contact scPharmaceuticals?

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at (617) 517-0730 or via email at [email protected].